Inhibrx Biosciences, Inc. (INBX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inhibrx Biosciences, Inc. (INBX) has a cash flow conversion efficiency ratio of 1.808x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.03 Million) by net assets ($-21.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see INBX market cap overview for the company's overall valuation and market capitalisation.
Inhibrx Biosciences, Inc. - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Inhibrx Biosciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Inhibrx Biosciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inhibrx Biosciences, Inc. ranked by their cash flow conversion efficiency. Explore INBX cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Global Brands Manufacture Ltd
TW:6191
|
0.059x |
|
The Karnataka Bank Limited
NSE:KTKBANK
|
0.177x |
|
Yunnan Salt & Salt Chemical Industry Co Ltd
SHE:002053
|
0.031x |
|
Parade Technologies Ltd
TWO:4966
|
0.024x |
|
National Vision Holdings Inc
NASDAQ:EYE
|
0.009x |
|
SkiStar AB (publ)
ST:SKIS-B
|
0.072x |
|
Loma Negra Compania Industrial Argentina SA ADR
NYSE:LOMA
|
0.016x |
|
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.
SHG:605016
|
0.022x |
Annual Cash Flow Conversion Efficiency for Inhibrx Biosciences, Inc. (2016–2025)
The table below shows the annual cash flow conversion efficiency of Inhibrx Biosciences, Inc. from 2016 to 2025. View Inhibrx Biosciences, Inc. share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.99 Million | $-129.79 Million | -16.238x | -1015.79% |
| 2024-12-31 | $133.58 Million | $-194.41 Million | -1.455x | +67.25% |
| 2023-12-31 | $43.50 Million | $-193.31 Million | -4.444x | -123.75% |
| 2022-12-31 | $58.06 Million | $-115.30 Million | -1.986x | -29.52% |
| 2021-12-31 | $52.38 Million | $-80.32 Million | -1.533x | -141.26% |
| 2020-12-31 | $75.47 Million | $-47.97 Million | -0.636x | -285.38% |
| 2019-12-31 | $-93.57 Million | $-32.08 Million | 0.343x | -14.42% |
| 2018-12-31 | $-57.64 Million | $-23.09 Million | 0.401x | -52.10% |
| 2017-12-31 | $-22.42 Million | $-18.75 Million | 0.836x | +105.72% |
| 2016-12-31 | $1.24 Million | $-18.11 Million | -14.615x | -- |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-bas… Read more